Press release
CUSTICS Launches Hautuki as an OTC Product in Singapore
According to a company representative, Hautuki was developed by CUSTICS Co., Ltd. using TDDS technology previously acquired from Seoul National University. This innovative patch integrates vitamins and various nutrients and is specifically designed to support children's growth.
Image: https://www.abnewswire.com/uploads/85ea01f2e25cff2bd5d8e29463a3d6d2.png
The technology is the "Pore-Permeable Transdermal Peptide Ligand," a patented innovation from the Department of Bio engineering at Seoul National University. This technology is particularly useful for facilitating the delivery of large active ingredients through the skin, enhancing the efficacy of transdermal administration.
A representative from Hautuki stated, "In addition to the FDA OTC registration, we are pursuing other certifications as well. We advise caution when purchasing from sources other than our official store, as products from unofficial channels may be counterfeit."
They added, "We will continue to work diligently to ensure that Hautuki consumers can purchase without doubt.
Image: https://www.abnewswire.com/uploads/2c37f8c063f1bcf120de786aa6c6944d.png
Diagram of a transdermal delivery peptide that penetrates the skin through pores, originally filed by Seoul National University Industry Foundation on March 11, 2011, and transferred to Custics Co., Ltd. on February 8, 2021.
Official mall : Hautuki Singapore [http://hautuki.sg/]
Patent Information : Hautuki's Patent Technology [https://patents.google.com/patent/KR101327555B1/en]
DISTRIBUTOR'S NAME - Amit Biswas
DISTRIBUTOR'S COMPANY - GWA
DISTRIBUTOR'S PHONE NUMBER 7001189925
Media Contact
Company Name: CUSTICS SINGAPORE PTE. LTD.
Contact Person: Media Relation Management
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=custics-launches-hautuki-as-an-otc-product-in-singapore]
Country: Singapore
Website: https://hautuki.sg/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CUSTICS Launches Hautuki as an OTC Product in Singapore here
News-ID: 3631824 • Views: …
More Releases from ABNewswire
Fibromyalgia Treatment Landscape: FDA Approves TONMYA, First New Therapy in 15 Y …
DelveInsight Business Research's latest report highlights the transformative impact of the FDA's approval of TONMYA (cyclobenzaprine HCl sublingual tablets) by Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP). This landmark approval marks the first new fibromyalgia treatment approved by the FDA in more than 15 years, offering new hope for millions of patients suffering from this debilitating chronic pain condition.
Key Fibromyalgia Market Highlights
*
TONMYA's approval is expected to be a key driver…
Amyotrophic Lateral Sclerosis Clinical Trials, Companies, Therapies, Pipeline | …
DelveInsight's, "Amyotrophic Lateral Sclerosis (ALS) - Pipeline Insight, 2025," report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis (ALS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
DelveInsight reports that the Amyotrophic Lateral Sclerosis (ALS) pipeline involves over 75 key companies actively developing…
Extensive-Stage Small Cell Lung Cancer (ESCLC) Clinical Trials, Companies, Thera …
DelveInsight's, "Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
DelveInsight reports that the Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline involves…
Primary Ciliary Dyskinesia Clinical Trials, Companies, Therapies, Pipeline | Par …
DelveInsight's, "Primary Ciliary Dyskinesia - Pipeline Insight, 2025," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Primary Ciliary Dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Primary Ciliary Dyskinesia Pipeline constitutes 4+ key companies…
More Releases for Hautuki
Hautuki Patch Demonstrates Growth Potential and Safety in Clinical Study
Hautuki Clinically Proven to Support Height Growth and Ensure Safety
Custics announced that its height-supporting nutrient patch, Hautuki, has been proven effective and safe through a clinical study conducted at Bestian Hospital over the course of approximately one year.
Image: https://www.abnewswire.com/upload/2025/05/75daaface7cea909f35fd494150fea0f.PNG
The study was conducted over 11 months, from January to November 2024, and involved 40 children between the ages of 5 and 12.
After eight weeks, the group that used the Hautuki patch…
CUSTICS SINGAPORE's Growth Nutrient Patch 'Hautuki' Completes Clinical Study
Image: https://www.abnewswire.com/upload/2025/01/d0c11fb6ef950d96ffc92b987934691b.jpg
CUSTICS SINGAPORE PTE. LTD. (hereafter referred to as "CUSTICS SINGAPORE [https://hautuki.sg/]") has successfully completed clinical study on its 'Hautuki [https://hautuki.sg/]' growth nutrient patch in collaboration with Bestian Hospital, demonstrating its effectiveness in promoting height growth and confirming its safety. The study was conducted in adherence to Good Clinical Practice (GCP) standards and the approval of the Institutional Review Board (IRB), ensuring its reliability.
From January to November 2024, the study…
Hautuki, A Globally Recognized Innovative Patch Type Nutrition Solution for Chil …
Hautuki, an innovative children's nutrition product manufactured in South Korea, is gaining global recognition. Exported to countries including the United States, Singapore, Hong Kong, Taiwan, Malaysia, Indonesia, China, and the Philippines, Hautuki has established itself as a trusted brand in international markets.
CUSTICS, the company behind Hautuki, operates legal entities in South Korea, Singapore, Taiwan, and Hong Kong, strengthening its global presence. Based on its vision to "shine and illuminate," CUSTICS…
HAUTUKI Innovates Efficient Vitamin D Delivery for Children through Transdermal …
Recent nutritional surveys conducted both domestically and internationally indicate that more than 80% of children in their growth phase suffer from vitamin D deficiency or insufficiency. Research also shows that children with stunted growth are more prone to vitamin D deficiency compared to their peers. In countries with frequent rainy or overcast days, ensuring adequate vitamin D intake is naturally more challenging.
Image: https://www.abnewswire.com/uploads/d2d7d3db97fca5f29490d3971d5e13d5.jpg
CUSTICS Inc. (CEO LEE KANG IL), in their…
Custics Singapore's HAUTUKI Secures FDA OTC Product Registration and Excels in S …
Custics Singapore announces that HAUTUKI has achieved a significant milestone by securing registration as an OTC Product with the U.S. FDA
HAUTUKI, a cutting-edge product developed through technology transferred from Seoul National University, integrates a unique blend of vitamins and nutrients designed to amplify its effectiveness. At the core of HAUTUKI's innovation is a patented peptide ligand from the Department of Biotechnology at Seoul National University. This advanced technology is engineered…
Hautuki Introduces Safe and Easy Supplements: Skin-Friendly, Hassle-Free Patch S …
Image: https://www.abnewswire.com/uploads/362587e5d32397d9e2bf61339b424669.png
Singapore - 9 Aug, 2024 - Custics announced the release of "Hautuki," a height growth supplement using patented peptide technology developed by the Department of Biotechnology at Seoul National University.
A Custics official stated that the peptide technology promotes the intracellular delivery of nutrients, enhancing absorption without the need for oral administration. "Hautuki" is registered with the U.S. FDA OTC and has passed skin irritation tests with zero score.
The supplement…
